Business Description
Biofrontera AG
ISIN : DE000A4BGGM7
Total Employee Number:
69Compare
Compare
Traded in other countries / regions
B8FK.Germany0DOL.UKBIFRF.USA IPO Date
2009-10-01Description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.91 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -2.28 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -5.36 | |||||
Beneish M-Score | -2.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -38.7 | |||||
3-Year EBITDA Growth Rate | 81.9 | |||||
3-Year EPS without NRI Growth Rate | 58.7 | |||||
3-Year FCF Growth Rate | 25.7 | |||||
3-Year Book Growth Rate | -28.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.87 | |||||
9-Day RSI | 52.12 | |||||
14-Day RSI | 46.97 | |||||
3-1 Month Momentum % | -8.4 | |||||
6-1 Month Momentum % | -90.22 | |||||
12-1 Month Momentum % | -90.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.96 | |||||
Quick Ratio | 2.16 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 634.4 | |||||
Days Sales Outstanding | 104.37 | |||||
Days Payable | 242.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -26 | |||||
Shareholder Yield % | 2.37 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.41 | |||||
Operating Margin % | -9.02 | |||||
Net Margin % | -17.92 | |||||
EBITDA Margin % | -3.73 | |||||
FCF Margin % | -32.66 | |||||
OCF Margin % | -32.28 | |||||
ROE % | -14.98 | |||||
ROA % | -10.76 | |||||
ROIC % | -7.47 | |||||
3-Year ROIIC % | 41.42 | |||||
ROC (Joel Greenblatt) % | -15.41 | |||||
ROCE % | -5.64 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.03 | |||||
PB Ratio | 0.82 | |||||
Price-to-Tangible-Book | 0.83 | |||||
EV-to-EBIT | -10.27 | |||||
EV-to-EBITDA | -18.95 | |||||
EV-to-Revenue | 0.7 | |||||
EV-to-Forward-Revenue | 1.56 | |||||
EV-to-FCF | -2.16 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Median-PS-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 1.86 | |||||
| Price-to-Net-Cash | 240 | |||||
Earnings Yield (Greenblatt) % | -9.74 | |||||
FCF Yield % | -31.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biofrontera AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 13.63 | ||
| EPS (TTM) (€) | -0.404 | ||
| Beta | -1.9601 | ||
| 3-Year Sharpe Ratio | -0.72 | ||
| 3-Year Sortino Ratio | -0.72 | ||
| Volatility % | 88.65 | ||
| 14-Day RSI | 46.97 | ||
| 14-Day ATR (€) | 0.032823 | ||
| 20-Day SMA (€) | 2.3915 | ||
| 12-1 Month Momentum % | -90.22 | ||
| 52-Week Range (€) | 2.24 - 24.54688 | ||
| Shares Outstanding (Mil) | 6.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biofrontera AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biofrontera AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.047619:1 Stock Split | 2024-05-14 | 24.55 (+0.00%) |
Show
Entries
Biofrontera AG Frequently Asked Questions
What is Biofrontera AG(LTS:0DOL)'s stock price today?
The current price of LTS:0DOL is €2.40. The 52 week high of LTS:0DOL is €24.55 and 52 week low is €2.24.
When is next earnings date of Biofrontera AG(LTS:0DOL)?
The next earnings date of Biofrontera AG(LTS:0DOL) is .
Does Biofrontera AG(LTS:0DOL) pay dividends? If so, how much?
Biofrontera AG(LTS:0DOL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Biofrontera AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers